CSI Market
Sign In | Register

H cyte Inc (HCYT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access HCYT Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how H cyte Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2023)
3 Months 		(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Operating Activities
Income-2.09
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.02
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.04
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Consulting Services-
Common Stock Issued For Bonuses-
Equitybased Severance Payments-
Equitybased Directors Fees-
Increase Decrease In Contract With Customer Liability-
Interest And Penalties On Extension Of Shortterm Convertible Notes-
Income From Change In Fair Value Adjustment Of Derivative Liability Warrants-
Issuance Of Warrants To Extend Shortterm Debt-
Change In Fair Value Of Derivative Liability Warrants And Redemption Put Liability-
Derivative Loss On Derivative-
Change In Fair Value Of Redemption Put Liability-
Issuance Of Warrants Pursuant To Extension Of Maturity Date On Convertible Debt-
Gains Losses On Extinguishment Of Debt P P P Loans-
Forgiveness Of P P P Loan-
Issuance Of Warrants Pursuant To Extend Shortterm Notes Related Party-
Warrant Modification Expense-
Adjustment For Inducement Expense-
Loss On Convertible Notes1.52
Inducement Expense0.00
Increase Decrease In Patient Financing Receivable Net Of Current Portion0.00
Increase Decease Interest Payable Related Party0.07
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable, Trade0.07
Accrued Expense0.04
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.12
Other Working Capital0.08
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.01
Discontinued operations0.00
Net Cash flow from Operating Activities-0.36
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Net Assets Not Included In Purchase Transaction-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.02
Other borrowing transactions0.00
Long-term debt - borrowings0.30
Long-term debt - repayments-0.12
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock From Underwriters Overallotment-
Adjustment Of Fair Value Of Warrant Modification-
Payments On Note Payable Obligations-
Payment On Preferred Stock Series B Redemption-
Proceeds From Issuance Of Preferred Stock Series D-
Proceeds From Paycheck Protection Plan-
Proceeds From Warrants Exercised Related To Inducement-
Convertible Notes Payable Carried At Fair Value Related Party0.28
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.48
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.36
Total Cash Flow0.12
4 historic quarters locked

Sign in to unlock the full H cyte Inc cash flow history.

Sign In Create Free Account

About Innoveren Scientific Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-23-041399

Figures are derived from filed reports and may be restated. Historical data is subject to revision.